Zylox-Tonbridge Medical Technology Co., Ltd.

HKSE 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -2.53%

Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) is -2.53% for the year ending December 31, 2023, a 30.35% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -3.64%, a 46.26% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -6.77%, a 69.32% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -22.06%, a 44.09% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -39.46%.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
Loading...
HKSE: 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd.

CEO Dr. Zhong Zhao Ph.D.
IPO Date July 5, 2021
Location China
Headquarters Building 1
Employees 756
Sector Health Care
Industries
Description

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.

Similar companies

2162.HK

Keymed Biosciences Inc.

USD 3.69

1.93%

2170.HK

Suzhou Basecare Medical Corporation Limited

USD 0.37

-0.71%

StockViz Staff

January 15, 2025

Any question? Send us an email